Interleukin (IL)-1/IL-6-Inhibitor-Associated Drug Reaction With Eosinophilia and Systemic Symptoms (DReSS) in Systemic Inflammatory Illnesses.
Interleukin (IL)-1/IL-6-Inhibitor-Associated Drug Reaction With Eosinophilia and Systemic Symptoms (DReSS) in Systemic Inflammatory Illnesses. J Allergy Clin Immunol Pract. 2024 Aug 15.
PMID: 39002722
Risk factors for haemodynamic compromise in multisystem inflammatory syndrome in children: a multicentre retrospective study.
Risk factors for haemodynamic compromise in multisystem inflammatory syndrome in children: a multicentre retrospective study. Rheumatology (Oxford). 2023 08 01; 62(8):2829-2837.
PMID: 36583552
Multisystem Inflammatory Syndrome in Children.
Multisystem Inflammatory Syndrome in Children. Pediatr Ann. 2023 Mar; 52(3):e114-e121.
PMID: 36881797
Risk factors for haemodynamic compromise in multisystem inflammatory syndrome in children-a multicentre retrospective study.
Risk factors for haemodynamic compromise in multisystem inflammatory syndrome in children-a multicentre retrospective study. Rheumatology (Oxford). 2022 Dec 30.
PMID: 36583552
Multicenter Study of Utility and Acceptability of Depression and Anxiety Screening in Adolescents and Young Adults With Childhood-Onset Systemic Lupus.
Multicenter Study of Utility and Acceptability of Depression and Anxiety Screening in Adolescents and Young Adults With Childhood-Onset Systemic Lupus. Arthritis Care Res (Hoboken). 2023 04; 75(4):724-733.
PMID: 34806329
Juvenile Fibromyalgia in Patients With Juvenile Idiopathic Arthritis: Utility of the Pain and Symptom Assessment Tool.
Juvenile Fibromyalgia in Patients With Juvenile Idiopathic Arthritis: Utility of the Pain and Symptom Assessment Tool. Arthritis Care Res (Hoboken). 2022 12; 74(12):2085-2090.
PMID: 34197032
Adherence to medication by adolescents and young adults with childhood-onset systemic lupus erythematosus.
Adherence to medication by adolescents and young adults with childhood-onset systemic lupus erythematosus. Lupus. 2022 Oct; 31(12):1508-1515.
PMID: 35938626
2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging.
2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging. Arthritis Rheumatol. 2022 04; 74(4):570-585.
PMID: 35233961
2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis.
2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. Arthritis Rheumatol. 2022 04; 74(4):553-569.
PMID: 35233993
2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging.
2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging. Arthritis Care Res (Hoboken). 2022 04; 74(4):505-520.
PMID: 35233989